defibrotide

Single-stranded polydeoxyribonucleotide extracted from mammalian organs and used in the treatment of HEPATIC VENO-OCCLUSIVE DISEASE in patients with kidney or lung abnormalities following HEMATOPOIETIC STEM CELL TRANSPLANTATION

Also Known As:

Networked: 285 relevant articles (33 outcomes, 51 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Richardson, Paul G: 19 articles (01/2022 - 06/2007)
2.	Iacobelli, Massimo: 13 articles (01/2020 - 01/2006)
3.	Corbacioglu, Selim: 10 articles (06/2022 - 04/2012)
4.	Kernan, Nancy A: 10 articles (12/2021 - 07/2010)
5.	Carreras, Enric: 8 articles (12/2021 - 08/2012)
6.	Lehmann, Leslie: 8 articles (01/2021 - 06/2012)
7.	Richardson, Paul: 7 articles (12/2019 - 01/2006)
8.	Antin, Joseph H: 7 articles (10/2018 - 07/2010)
9.	Grupp, Stephan A: 6 articles (01/2021 - 03/2016)
10.	Smith, Angela R: 6 articles (01/2021 - 01/2017)

Related Diseases

1.	Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive) 08/01/2012 - "Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease." 05/01/2023 - "Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial." 01/01/2023 - "Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study." 06/01/2022 - "A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome." 12/01/2019 - "Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)."
2.	Thrombophlebitis 05/15/1989 - "The efficacy of defibrotide in the treatment of acute thrombophlebitis of the legs has been investigated in 140 patients, randomized into two groups. " 01/01/1986 - "To evaluate the efficacy of this drug against acute thrombophlebitis, we treated a group of 10 patients with 200 mg defibrotide intravenously three times a day for 15 days. " 05/15/1989 - "[Use of defibrotide in the treatment of acute superficial thrombophlebitis of the legs]." 01/01/1986 - "Defibrotide-treated patients showed a fast disappearance of clinical and instrumental signs of thrombophlebitis. " 12/15/1988 - "[Evaluation of the efficacy of profibrinolytic treatment with defibrotide in the therapy of thrombophlebitis]."
3.	Reperfusion Injury 12/01/2003 - "The protective mechanisms of defibrotide on liver ischaemia-reperfusion injury." 01/01/1993 - "In fact, we showed that defibrotide treatment significantly protected rat heart, kidney and liver from ischaemia and postischaemic reperfusion injury. " 10/01/1990 - "Protection of kidney from postischemic reperfusion injury in rats treated with defibrotide." 01/01/1989 - "We studied the effect of defibrotide administration in protecting liver and heart from ischaemic and postischaemic reperfusion damage. " 01/01/1988 - "Protection of the ischaemic myocardium from reperfusion injury by defibrotide and its possible mechanism of action."
4.	Venous Thrombosis (Deep-Vein Thrombosis) 07/01/1988 - "In an open multicenter comparative study aimed at the evaluation of the efficacy of defibrotide in the prophylaxis of postsurgical deep vein thromboses (DVT) an ad interim evaluation has been made on 2626 patients thus far enrolled. " 01/01/2022 - "We used in vitro assays and a mouse model to determine the mechanisms by which defibrotide inhibits NET formation and venous thrombosis in APS. " 01/01/1992 - "Prophylaxis of venous thrombosis after gynaecological surgery: a controlled pilot study of defibrotide." 06/01/1989 - "In the calciheparin group, the trend of certain examinations shows, as usual, a change in parameters in agreement with the drug's anticlotting action; in the group treated with defibrotide, the haemostatic balance is respected: the angiographies never showed intimal lesion or phlebothrombosis in either group. " 05/31/1989 - "[A multicenter study of defibrotide in the prevention of deep venous thrombosis. "
5.	Thrombosis (Thrombus) 01/01/1987 - "The results show that Defibrotide is highly effective in reducing the size of the thrombus. " 10/01/1989 - "Defibrotide was effective against 3-, 7-, or 10-day-old thrombi; its ED50s were 32, 65, or 118 mg/kg-1 hour-1, respectively, suggesting that the age of the thrombus could play a role in the outcome of thrombolysis. " 01/01/2017 - "In this study, we aimed to investigate the additive effect of mesenchymal stem cells (MSC) and defibrotide (DFT) in a rat model of femoral arterial thrombosis. " 01/01/2022 - "Defibrotide inhibits NET-mediated thrombosis in APS models." 01/01/2017 - "Additive effect of mesenchymal stem cells and defibrotide in an arterial rat thrombosis model."

Related Drugs and Biologics

1.	Polydeoxyribonucleotides
2.	calcium heparin (Calciparine)
3.	Epoprostenol (Prostacyclin)
4.	DNA (Deoxyribonucleic Acid)
5.	Fibrin
6.	axicabtagene ciloleucel
7.	Cyclophosphamide (Cytoxan)
8.	Dactinomycin (Actinomycin)
9.	Antithrombin III
10.	Protective Agents

Related Therapies and Procedures

1.	Stem Cell Transplantation
2.	Therapeutics
3.	Radiotherapy
4.	Cell Transplantation
5.	Gynecologic Surgical Procedures (Gynecologic Surgery)